JL
Insider
Joseph P Lyssikatos
CHIEF SCIENTIFIC OFFICERJoseph P Lyssikatos (CHIEF SCIENTIFIC OFFICER) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Enliven Therapeutics, Inc. (ELVN). The largest single filing was $3.5M of ELVN (132,500 sh across 4 lots, as filed), executed Jan 8.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
5
0 buys · 5 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$4.7M
shares × price, as filed
Last traded
Feb 6
Filed Feb 10
Median ADV $83.7M across their filed names
Open performance→Volume by month
Buys $0
Sells $7.5M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
5 filings
Sector per market data · by filing · past 12 months
Most traded names
ELVNRecent filings
ELVNSALE
Enliven Therapeutics, Inc.
View filing →
$150K7,500 sh × $20.03
Exec Jun 3 2025
Filed Jun 5 2025 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $101K
5,030 sh × $20.07
Exec May 1 2025
Filed May 5 2025 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $258K
12,500 sh × $20.61
Exec Mar 19 2025
Filed Mar 21 2025 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $1.4M
51,045 sh across 3 lots
Exec Oct 8 2024
Filed Oct 10 2024 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $207K
7,522 sh × $27.51
Exec Oct 4 2024
Filed Oct 8 2024 · 5:30 PM ET